Page last updated: 2024-09-02

tamibarotene and Triple Negative Breast Neoplasms

tamibarotene has been researched along with Triple Negative Breast Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bansal, N; Bosch, A; Cubedo, E; Farias, E; Fishel, M; Jones, JW; Kane, M; Leibovitch, B; Pereira, L; Pierzchalski, K; Waxman, S; Yu, J; Zelent, A	1

Other Studies

1 other study(ies) available for tamibarotene and Triple Negative Breast Neoplasms

Article	Year
Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer. Oncotarget, 2016, Jul-12, Volume: 7, Issue:28 Topics: Animals; Antineoplastic Agents; Benzoates; Carcinogenesis; Cell Line, Tumor; Female; Humans; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Receptors, Retinoic Acid; Repressor Proteins; Sin3 Histone Deacetylase and Corepressor Complex; Tetrahydronaphthalenes; Thiazoles; Triple Negative Breast Neoplasms	2016

Article

Year

Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer.

Oncotarget, 2016, Jul-12, Volume: 7, Issue:28

Topics: Animals; Antineoplastic Agents; Benzoates; Carcinogenesis; Cell Line, Tumor; Female; Humans; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Receptors, Retinoic Acid; Repressor Proteins; Sin3 Histone Deacetylase and Corepressor Complex; Tetrahydronaphthalenes; Thiazoles; Triple Negative Breast Neoplasms

2016